Initiating





☐ Ensure that treating prescribers and pharmacists have Risk Evaluation and Mitigation Strategy

☐ Perform benefits investigation (eg, J-Code, New Technology Add-On Payment [NTAP]) and obtain



TECVAYLI® and TALVEY® are two distinct bispecific antibodies with differences in dosing and administration, safety, and use.

This reference guide provides helpful information for initiating treatment with TECVAYLI® or TALVEY®. This is not intended to be a comprehensive list, and individual practices should follow their own required procedures.

This checklist is intended for institutions initiating treatment for TECVAYLI® or TALVEY®.

Healthcare Team Preparation

TECVAYLI® treatment

(REMS) certification

Providers may utilize this checklist for their practice while either treating patients or arranging treatment at another facility.

Preparing to Initiate Treatment					

prior authorization, if required ☐ Dosing Ordering Information:
☐ TECVAYLI®: Order 30 mg/3 mL vial size for step-up dose 1 and step-up dose 2 and 153 mg/1.7 mL vial size for the first treatment dose; use Tables 7, 8, and 9 in the full Prescribing Information to determine number of vials required based on patient's actual body weight
☐ TALVEY®: Order 3 mg/1.5 mL (2 mg/mL) vial size for the step-up dosing schedule and 40 mg/mL vial size for the first treatment dose; use Tables 9, 10, 11, and 12 in the full Prescribing Information to determine number of vials required based on patient's actual body weight
 Determine bed availability and coordinate with the healthcare team for patient's hospitalization period Provide education for staff regarding step-up dosing schedule, Adverse Reactions (ARs) monitoring/management, and reporting protocols
☐ Ensure supportive therapies are available for Cytokine Release Syndrome (CRS) and Neurologic

Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Please see the TECVAYLI® Dosing and AR Management Guide, the TALVEY® Treatment Management Guide or the TECVAYLI® and TALVEY® Adverse Reaction Management Guide for reference. ☐ Administer pretreatment medications as specified in the respective product's full Prescribing Information ☐ TECVAYLI®: Consider initiation of antiviral prophylaxis to prevent herpes zoster reactions per guidelines prior to

☐ Complete the Patient Wallet Card based on the drug prescribed and provide patients with the TECVAYLI® or

☐ Request all necessary patient records from the referring treatment practice



Patient/Caregiver **Education and Logistics** for Initiating Treatment

TALVEY® Patient Wallet Card and the Patient Starter Kit Caregiver Wallet Card prior to treatment initiation (first dose) Confirm the patient has received and is carrying the Patient Wallet Card
Communicate and outline the step-up dosing schedule and administrative logistics to patients and their caregivers □ Ensure that the patient has support for each dose during the step-up dosing schedule, including travel and transportation, if needed
☐ Provide guidance to patients and caregivers regarding any potential side effects Please see section 17 in the TECVAYLI® full Prescribing Information and the TALVEY® full Prescribing Information for patient counseling information.
□ Ensure care team has scheduled the next treatment dose with the patient to ensure treatment continuity
□ Provide and advise the patient to read the Medication Guide
 □ Share the TECVAYLI® Patient Brochure, Getting Started Guide, with patients □ Share the TECVAYLI® Caregiver Brochure with family members/caregivers □ Share the TALVEY® Patient Brochure, My Journey With TALVEY®, with patients □ Share the TALVEY® Caregiver Brochure with family members/caregivers □ Provide resources for financial assistance to patients and caregivers, including: Janssen CarePath at janssencarepath.com Janssen Compass® at janssencompass.com
Provide patients and caregivers information regarding the closest hospital in case of an emergency
Ensure that patients and their caregivers know who to talk to if they are experiencing or think they may be experiencing a side effect related to treatment
Confirm the patient has received and is carrying the Patient Wallet Card



Communicate with the ongoing treatment site to ensure success	sful transfer of patient
□ Ensure that treating prescribers and pharmacists have	REMS certification
Converd only important discharge information, treatment notes	and records to angein

- \square Forward any important discharge information, treatment notes, and records to ongoing treatment site
- ☐ Ensure that the prior authorization for TECVAYLI® or TALVEY® is closed out so the ongoing treatment facility can open a new prior authorization for the patient
- ☐ Ensure the ongoing treatment facility has supportive therapies available for ongoing treatment

Initiating







Other Resources

Janssen CarePath **Resource Guide**

REMS Fact Sheet and Cover Letter



- ☐ Discuss next steps with the patient regarding their ongoing treatment plan with TECVAYLI® or TALVEY®
- ☐ Discuss with the patient's caregiver(s) the importance of their role. If appropriate, consider giving the specific caregiver support resources
- ☐ Provide the treatment center contact information for patients and caregivers in case there are any potential health problems or complications, or in case patients want to remain in contact with the treatment center where they initiated treatment
- ☐ Provide patients and caregivers information regarding the closest hospital in case of an emergency
- ☐ Ensure that patients and their caregivers know who to talk to if they are experiencing or think they may be experiencing a side effect related to treatment
- ☐ Confirm the patient/caregiver continues to carry the Patient and/or Caregiver Wallet Card



TECVAYLI®



TECVAYLI® Prescribing Information



TALVEY®



TALVEY® Prescribing Information



TALVEY® Medication Guide



TALVEY® Treatment **Management Guide**



TALVEY® Patient Brochure



My Journey With TALVEY®



TALVEY® Caregiver Brochure



TECVAYLI® Dosing and AR **Management Guide**



TECVAYLI® Patient Brochure



TECVAYLI® Getting Started Guide



TECVAYLI® Caregiver Brochure